US equities |
INTC $63.94 ▼-30.55% NVDA $202.92 ▼-5.03% MU $870.01 ▼-6.88% AMZN $239.03 ▼-1.95% SNDK $1,137.31 ▼-14.49% AMD $499.25 ▼-11.86% GOOGL $277.86 ▼-2.10% AAPL $343.50 ▼-1.55%
FinancialContent

Vanda Pharmaceuticals Inc. - Common Stock (NQ:VNDA)

3.785 -0.265 (-6.54%)
Delayed Quote Updated: 3:28 PM EDT, Oct 30, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Vanda Pharmaceuticals Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
News headline image
Vanda (VNDA) Q3 2026 Earnings Call Transcript ↗
Revenue surged 24% year over year, driven by Fanapt growth and NEREUS launch momentum. 
Via The Motley Fool
Topics Earnings
News headline image
Vanda Pharmaceuticals Q3 Earnings Call Highlights ↗
Vanda Pharmaceuticals (NASDAQ:VNDA) reported third-quarter revenue growth of 24% from a year earlier, supported by higher Fanapt sales and a sharp sequential increase in HETLIOZ revenue tied partly to... 
Via MarketBeat
Topics Earnings
News headline image
Vanda (VNDA) Q2 2026 Earnings Call Transcript ↗
Fanapt surges 23% as Vanda expands psychiatry franchise amid pipeline progress. 
Via The Motley Fool
Topics Earnings
VANDA PHARMACEUTICALS INC (NASDAQ:VNDA) Misses Q1 2026 Estimates as Top-Line Growth Slows ↗
Via Chartmill
Why Did Vanda Pharmaceuticals Stock Slide 7% Pre-Market Today? ↗
Via Stocktwits
Vanda Pharmaceuticals Inc (NASDAQ:VNDA) Stock Plummets 9.8% After Mixed Q4 2025 Earnings Report ↗
Via Chartmill
News headline image
Vanda Pharmaceuticals Q2 Earnings Call Highlights ↗
Vanda Pharmaceuticals (NASDAQ:VNDA) reported second-quarter 2026 revenue of $50.5 million, down 4% from a year earlier, as growth in Fanapt and PONVORY was offset by lower HETLIOZ sales amid generic... 
Via MarketBeat
Topics Earnings
News headline image
Vanda (VNDA) Q1 2026 Earnings Call Transcript ↗
Vanda (VNDA) Q1 2026 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings Intellectual Property
Curious about the stocks that are showing activity after the closing bell on Friday? ↗
Via Chartmill
Vanda Stock Drop 10% Premarket After FDA Rejects Jet Lag Drug Application ↗
Via Stocktwits
News headline image
Vanda Now Looks To Public Hearing For Hetlioz In Jet Lag Disorder After Multiple FDA Rejections ↗
According to Vanda, the FDA has not granted such a hearing in the context of drug approvals for potentially over 40 years. 
Via Stocktwits
News headline image
Vanda Pharma Stock Rises Pre-Market After FDA Accepts Imsidolimab Filing For Rare Skin Disorder ↗
The company noted that if the FDA approves its application, Imosidolimab could address a significant unmet medical need in this rare and life-threatening disorder. 
Via Stocktwits
In today's session, these stocks are experiencing unusual volume. ↗
Via Chartmill
Let's take a look at the stocks that are in motion in today's session. ↗
Via Chartmill
Here are the top movers in Monday's session. ↗
Via Chartmill
These stocks are gapping in today's session ↗
Via Chartmill
These stocks are moving in today's pre-market session ↗
Via Chartmill
News headline image
Nasdaq, S&P 500 Futures Fall On Tariff, Iran Tensions: Why NVDA, NFLX, HON, IBRX, MLTX Are On Traders' Radar Today ↗
Data from Stocktwits indicated retail sentiment on SPY and QQQ has been ‘bearish’. 
Via Stocktwits
Topics Artificial Intelligence ETFs Government
News headline image
VNDA Stock Soars 40% Overnight After Bysanti Approval: What’s The Next Catalyst And How Much Upside Remains? ↗
Vanda said it expects Bysanti to be available in the market in the third quarter of 2026. 
Via Stocktwits
News headline image
VNDA Stock Rallies After-Hours As FDA Approves Schizophrenia, Bipolar Disorder Drug ↗
This is the second Vanda drug to be approved in the span of a few months, after the approval of Nereus in December. 
Via Stocktwits
News headline image
Vanda Stock Draws Heavy Buzz Ahead Of FDA Verdict On Bysanti For Bipolar, Schizophrenia ↗
The company said that if approved, Bysanti could be available for sale in the U.S. this year. 
Via Stocktwits
News headline image
Vanda (VNDA) Q4 2025 Earnings Call Transcript ↗
Vanda (VNDA) Q4 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Vanda Pharmaceuticals Inc. - VNDA
From Pomerantz LLP
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Vanda Pharmaceuticals Inc. - VNDA
From Pomerantz LLP
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Vanda Pharmaceuticals Inc. - VNDA
From Pomerantz LLP
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Vanda Pharmaceuticals Inc. - VNDA
From Pomerantz LLP
Via GlobeNewswire
Get insights into the top gainers and losers of Thursday's pre-market session. ↗
Via Chartmill
In today's session, these stocks are experiencing unusual volume. ↗
Via Chartmill
News headline image
What&#39;s Going On With Vanda Pharmaceuticals Stock Wednesday? ↗
Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) shares are trading higher Wednesday after the company announced it received FDA approval of NEREUS for the prevention of vomiting induced by motion. 
Via Benzinga
Here are the top movers in Wednesday's session. ↗
Via Chartmill
< Previous 1 2 3 4 5 6 7 Next >